PMID- 11815242
OWN - NLM
STAT- MEDLINE
DCOM- 20020328
LR  - 20190702
IS  - 0027-5107 (Print)
IS  - 0027-5107 (Linking)
VI  - 514
IP  - 1-2
DP  - 2002 Feb 15
TI  - Cytogenetic effects of hexavalent chromium in Bulgarian chromium platers.
PG  - 29-38
AB  - The aim of the present study was to evaluate the genotoxic effects of hexavalent 
      chromium (Cr(VI)) in vivo in exposed Bulgarian chromium platers by using 
      classical cytogenetic and molecular cytogenetic analyses of peripheral 
      lymphocytes and exfoliated buccal cells. No significant difference was observed 
      between the exposed workers and the controls with regard to the frequency of 
      cells with chromosome aberrations (CAs) using conventional Giemsa staining and in 
      the frequency of sister chromatid exchanges (SCEs). However, there was a 
      significant increase in the number of cells with micronuclei (MN) in peripheral 
      lymphocytes from chromium exposed workers as compared to the controls. In the 
      buccal cells from these workers, this increase was even more pronounced. Cytosine 
      arabinoside (AraC), an inhibitor of DNA synthesis and repair, was found to 
      significantly increase the levels of MN in vitro in the lymphocytes of both 
      groups. The increase was more expressed in the lymphocytes of chromium exposed 
      workers. Both centromere positive (C(+)) as well as centromere negative (C(-)) MN 
      were observed by the fluorescence in situ hybridization (FISH) technique in both 
      of the cell types studied. No difference between C(+) and C(-) MN frequencies was 
      found in the lymphocytes as well as in the buccal cells. Thus, Cr(VI) appears to 
      have both clastogenic as well as aneugenic effects in humans.
FAU - Benova, Donka
AU  - Benova D
AD  - National Center of Radiobiology and Radiation Protection (NCRRP), Laboratory of 
      Radiation Mutagenesis and Embryology, 132 Kliment Ochridski Blvd., 1756, Sofia, 
      Bulgaria. benova_ncrrp@medicalnet-bg.org
FAU - Hadjidekova, Valeria
AU  - Hadjidekova V
FAU - Hristova, Rossitza
AU  - Hristova R
FAU - Nikolova, Teodora
AU  - Nikolova T
FAU - Boulanova, Minka
AU  - Boulanova M
FAU - Georgieva, Ivanka
AU  - Georgieva I
FAU - Grigorova, Mira
AU  - Grigorova M
FAU - Popov, Todor
AU  - Popov T
FAU - Panev, Teodor
AU  - Panev T
FAU - Georgieva, Rossitza
AU  - Georgieva R
FAU - Natarajan, Adayapalam T
AU  - Natarajan AT
FAU - Darroudi, Firouz
AU  - Darroudi F
FAU - Nilsson, Robert
AU  - Nilsson R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Mutat Res
JT  - Mutation research
JID - 0400763
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0 (Carcinogens, Environmental)
RN  - 04079A1RDZ (Cytarabine)
RN  - 0R0008Q3JB (Chromium)
RN  - 18540-29-9 (chromium hexavalent ion)
SB  - IM
CIN - Mutat Res. 2003 Jul 8;538(1-2):181-2; author reply 183-4. PMID: 12834767
MH  - Adult
MH  - Antimetabolites, Antineoplastic/pharmacology
MH  - Bulgaria
MH  - Carcinogens, Environmental/*toxicity
MH  - Cells, Cultured
MH  - Chromium/*toxicity
MH  - *Chromosome Aberrations
MH  - Cohort Studies
MH  - Cytarabine/pharmacology
MH  - Cytogenetic Analysis
MH  - Female
MH  - Humans
MH  - Inhalation Exposure
MH  - Lymphocytes/drug effects/physiology
MH  - Male
MH  - Micronuclei, Chromosome-Defective/metabolism
MH  - Micronucleus Tests
MH  - Middle Aged
MH  - Mouth Mucosa/cytology/drug effects/metabolism
MH  - Mutagenicity Tests
MH  - *Occupational Exposure
MH  - *Sister Chromatid Exchange
EDAT- 2002/01/30 10:00
MHDA- 2002/03/29 10:01
CRDT- 2002/01/30 10:00
PHST- 2002/01/30 10:00 [pubmed]
PHST- 2002/03/29 10:01 [medline]
PHST- 2002/01/30 10:00 [entrez]
AID - S1383571801003205 [pii]
AID - 10.1016/s1383-5718(01)00320-5 [doi]
PST - ppublish
SO  - Mutat Res. 2002 Feb 15;514(1-2):29-38. doi: 10.1016/s1383-5718(01)00320-5.